Braveheart Bio, Inc. Common Stock (BRVE) - Net Assets
Based on the latest financial reports, Braveheart Bio, Inc. Common Stock (BRVE) has net assets worth $-95.91 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($126.96 Million) and total liabilities ($222.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See net asset quality index of Braveheart Bio, Inc. Common Stock to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-95.91 Million |
| % of Total Assets | -75.54% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Braveheart Bio, Inc. Common Stock - Net Assets Trend (2025–2025)
This chart illustrates how Braveheart Bio, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for Braveheart Bio, Inc. Common Stock (2025–2025)
The table below shows the annual net assets of Braveheart Bio, Inc. Common Stock from 2025 to 2025. For live market cap and overall valuation, see Braveheart Bio, Inc. Common Stock market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-65.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Braveheart Bio, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $180.00K | % |
| Total Equity | $-65.87 Million | 100.00% |
Braveheart Bio, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Braveheart Bio, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LANXESS AG UNSP.ADR 1/5
F:LX9B
|
$1.72 Billion |
|
Shenzhen Hymson Laser Intelligent Equipments Co Ltd
SHG:688559
|
$1.72 Billion |
|
BBMG Corp Class A
SHG:601992
|
$1.72 Billion |
|
SoftwareONE Holding AG
SW:SWON
|
$1.72 Billion |
|
S&T Bancorp Inc
NASDAQ:STBA
|
$1.72 Billion |
|
Hope Bancorp Inc
NASDAQ:HOPE
|
$1.72 Billion |
|
Changbai Mountain Tourism Co Ltd
SHG:603099
|
$1.72 Billion |
|
NCAB Group
ST:NCAB
|
$1.72 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Braveheart Bio, Inc. Common Stock's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Braveheart Bio, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2025-12-31 | $-0.90 | $19.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Braveheart Bio, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-59.46 Million |
Industry Comparison
This section compares Braveheart Bio, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $121,148,904
- Average return on equity (ROE) among peers: -45.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Braveheart Bio, Inc. Common Stock (BRVE) | $-95.91 Million | 0.00% | N/A | $1.72 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $102.55 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $67.72 Million | -21.45% | 0.18x | $283.63 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $151.68 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $828.08 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.12 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $30.68 Million | -84.47% | 0.32x | $3.37 Billion |
About Braveheart Bio, Inc. Common Stock
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is he… Read more